STOCK TITAN

Abbott Laboratories - ABT STOCK NEWS

Welcome to our dedicated page for Abbott Laboratories news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories stock.

Abbott Laboratories (NYSE: ABT) is a globally recognized American multinational company headquartered in Abbott Park, Illinois. Founded in 1888, Abbott has established itself as a leader in medical devices and health care. The company manufactures and markets a wide range of products, including cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.

Abbott's product portfolio includes pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays along with point-of-care diagnostic equipment. Approximately 60% of Abbott’s sales are derived from markets outside the United States, underlining its global reach and influence.

Recently, Abbott introduced the PROTALITY™ brand, a high-protein nutrition shake aimed at supporting weight loss while preserving muscle mass. This innovation reflects Abbott's commitment to addressing global health challenges such as obesity and muscle health. The company also continues to make strides in medical technology with advancements like the TriClip™ system for tricuspid valve repair, and the FreeStyle Libre continuous glucose monitoring systems, which have set new standards in diabetes management.

Abbott is not only focused on innovative product development but also on strategic partnerships and sustainability. The extension of their partnership with the Real Madrid Foundation, aimed at reducing childhood malnutrition and promoting healthy habits, is a testament to their commitment to global health improvements.

Financially, Abbott has demonstrated robust performance, as evidenced by its consistent dividend payouts and its inclusion in the S&P 500 Dividend Aristocrats Index. The company reported strong Q1 2024 results with significant growth in their core business segments, further supported by successful product launches and clinical innovations.

Abbott’s mission to help people live more fully at all stages of life drives their development of life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. With a workforce of over 114,000 employees serving people in over 160 countries, Abbott continues to set benchmarks in the healthcare industry.

Rhea-AI Summary
Abbott (ABT) announces the first global procedures using the Volt Pulsed Field Ablation (PFA) System to treat patients with atrial fibrillation. The system uses high energy electrical pulses to destroy cells causing abnormal heart rhythms, reducing the risk of damaging adjacent tissue. The Volt PFA System is designed to overcome limitations of first-generation PFA systems and provide a more accurate and efficient workflow for physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
-
Rhea-AI Summary
Abbott (ABT) and Tandem Diabetes Care (TNDM) have announced the integration of the FreeStyle Libre 2 Plus sensor with the t:slim X2 insulin pump in the U.S. This marks the first time that Tandem's Control-IQ technology is compatible with the 15-day continuous glucose monitoring (CGM) sensor, providing a hybrid closed-loop system for users in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
-
Rhea-AI Summary
Abbott (NYSE: ABT) is set to announce its fourth-quarter 2023 financial results on January 24, 2024, before the market opens. The live webcast of the earnings conference call will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
Rhea-AI Summary
Abbott (NYSE: ABT) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences
-
Rhea-AI Summary
Abbott (NYSE: ABT) increases its quarterly common dividend by 7.8% to 55 cents per share, marking 52 years of consecutive dividend growth. The company will pay its 400th consecutive quarterly dividend since 1924 on Feb. 15, 2024. Abbott is a member of the S&P 500 Dividend Aristocrats Index, demonstrating its commitment to delivering strong shareholder returns and top-tier growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
dividends
-
Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announced the 36-month data from its TRANSCEND clinical trial, presenting the safety and efficacy of the SurVeil drug coated balloon (DCB) compared to the IN.PACT Admiral DCB for treating superficial femoral and proximal popliteal artery lesions. The primary efficacy and safety endpoints showed comparable outcomes, demonstrating the non-inferiority of the SurVeil DCB to the IN.PACT Admiral DCB. Dr. Peter A. Schneider presented the data at the 50th Annual VEITH Symposium in New York, New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none
Rhea-AI Summary
Abbott (NYSE: ABT) has announced new data from the ARIES trial, showing that advanced heart failure patients living with its HeartMate 3™ heart pump who didn't receive aspirin as part of their blood-thinning medication regimen experienced fewer complications from bleeding and were associated with reduced hospital visits compared to patients who took aspirin daily following their implant. The data from the ARIES trial is the first to potentially shift how physicians manage their patients living with a HeartMate 3 heart pump. The trial studied more than 600 patients and found that HeartMate 3 patients who didn't receive aspirin but continued using the standard post-implant vitamin-K antagonist (VKA) treatment regimen met the primary endpoint by showing non-inferiority of no aspirin to aspirin. The ARIES trial also revealed cost-savings for heart failure patients who did not take aspirin following implant of an Abbott HeartMate 3 pump, with a 41% reduction in estimated costs related to bleeding events one year after receiving the device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
none
-
Rhea-AI Summary
Abbott (NYSE: ABT) study shows Healthy Food Rx program's positive impact on diabetes management and diet quality in Stockton, Calif.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
none
-
Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announced that 36-month data from its TRANSCEND clinical trial will be presented at the 50th Annual VEITH Symposium. Dr. Peter A. Schneider will share the trial's safety and efficacy data in a session focused on randomized controlled trial updates on drug coated balloons and drug eluting stents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
Rhea-AI Summary
Abbott announced 'Countdown at a Crossroads,' a campaign to raise awareness of diabetes and promote access to continuous glucose monitoring (CGM) systems. The campaign includes an animated installation at the Oculus Center in New York City featuring people impacted by diabetes. Every visit to www.Crossroads.Abbott in November triggers a donation to the American Diabetes Association's Health Equity Now program. Abbott aims to make CGM technology more accessible and affordable, as only 1% of adults with diabetes currently use it.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none

FAQ

What is the current stock price of Abbott Laboratories (ABT)?

The current stock price of Abbott Laboratories (ABT) is $115.9 as of November 15, 2024.

What is the market cap of Abbott Laboratories (ABT)?

The market cap of Abbott Laboratories (ABT) is approximately 200.2B.

What does Abbott Laboratories specialize in?

Abbott Laboratories specializes in cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.

What are some of Abbott’s recent product launches?

Recent product launches include the PROTALITY™ high-protein nutrition shake and the TriClip™ system for tricuspid valve repair.

How much of Abbott’s sales are generated outside the United States?

Approximately 60% of Abbott’s sales are generated outside the United States.

What is Abbott’s PROTALITY™ brand?

The PROTALITY™ brand is a high-protein nutrition shake designed to support weight loss while preserving muscle mass, addressing global health challenges like obesity.

How does Abbott support global health initiatives?

Abbott supports global health initiatives through strategic partnerships like their collaboration with the Real Madrid Foundation to reduce childhood malnutrition and promote healthy habits.

What is Abbott’s financial performance like?

Abbott has demonstrated robust financial performance, with strong Q1 2024 results and a consistent track record of dividend payouts, evidenced by its inclusion in the S&P 500 Dividend Aristocrats Index.

How many employees does Abbott have?

Abbott employs over 114,000 people worldwide.

Which continuous glucose monitoring system is Abbott known for?

Abbott is known for its FreeStyle Libre continuous glucose monitoring systems, which are widely recognized for their innovation in diabetes management.

What is Abbott's mission?

Abbott's mission is to help people live more fully at all stages of life by developing life-changing technologies spanning diagnostics, medical devices, nutritionals, and branded generic medicines.

In how many countries does Abbott operate?

Abbott operates in more than 160 countries worldwide.

Abbott Laboratories

NYSE:ABT

ABT Rankings

ABT Stock Data

200.24B
1.73B
0.53%
78.64%
0.81%
Medical Devices
Pharmaceutical Preparations
Link
United States of America
ABBOTT PARK